Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial

In the MM-015 trial, melphalan–prednisone–lenalidomide followed by lenalidomide maintenance (MPR-R) significantly prolonged progression-free survival versus melphalan–prednisone (MP) in newly diagnosed patients with multiple myeloma aged ≥ 65 years. Health-related quality of life (HRQoL), a secondar...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios A., Palumbo, Antonio, Hajek, Roman, Kropff, Martin, Petrucci, Maria Teresa, Lewis, Philip, Millar, Stefanie, Zhang, Jingshan, Mei, Jay, Delforge, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2014
Materias:
Original Article: Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133972/
https://www.ncbi.nlm.nih.gov/pubmed/24144308
http://dx.doi.org/10.3109/10428194.2013.847933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133972/
https://www.ncbi.nlm.nih.gov/pubmed/24144308
http://dx.doi.org/10.3109/10428194.2013.847933

Ejemplares similares